Author

Chohee Yun 1

1 Gilead Sciences, Inc.,Foster City, CA,United States

CORTICOSTEROID-FREE REMISSION OF ULCERATIVE COLITIS WITH FILGOTINIB MAINTENANCE THERAPY: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Edward V Loftus Jr, Severine Vermeire, Brian Feagan, Chohee Yun, Jeremy Hsieh, Xiaopeng Liu, Sally Zhao, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Marc Ferrante, Alessandra Oortwijn, Chohee Yun, Jie Zhang, Laurent Peyrin-Biroulet, Severine Vermeire, Silvio Danese, Brian Feagan

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan, Edward V. Loftus, Jr., Silvio Danese, Severine Vermeire, William Sandborn, Tim Ritter, Rajiv Mehta, Ursula Seidler, Frank Seibold, Ian Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshifumi Hib

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet, Edward V. Loftus Jr., Silvio Danese, Severine Vermeire, William Sandborn, Ronald Fogel, Sandeep Nijhawan, Radoslaw Kempinski, Rafal Filip, Ihor Hospodarskyy, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshi

EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Amy Meng, Chia-Hsiang Hsueh, Liyun Ni, Cara Nelson, Chohee Yun

HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JAK1 INHIBITOR FILGOTINIB IN ACTIVE CROHN’S DISEASE: RESULTS FROM FITZROY STUDY

Walter Reinisch, Geert R. D'Haens, Gert De Hertogh, Annegret Van der Aa, Jenny Zhang, Chantal Tasset, Chohee Yun, Adrian Serone, Brian G. Feagan, William Sandborn, Severine Vermeire

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Silvio Danese, Timothy Ritter, Jason Dinoso, Jeremy Hsieh, Chohee Yun, Jie Zhang, Sally Zhao, Edward V Loftus Jr, Toshifumi Hibi, Gerhard Rogler

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet, Sally Zhao, Xiaopeng Liu, Gerhard Rogler, Chohee Yun, Jean-Frédéric Colombel, Brian Feagan, Christine Birchwood, Silvio Danese, Edward V. Loftus Jr, Toshifumi Hibi

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Stefan Schreiber, Mamoru Watanabe, Ulrik Moerch, Gerhard Rogler, Edward V Loftus Jr, Jeremy Hsieh, Yan Zhou, Sally Zhao, Chohee Yun

Item 1 - 9 / 9
1